story of the week
Pembrolizumab Plus Pomalidomide and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Haematology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Pembrolizumab Plus Pomalidomide and Dexamethasone for Patients With Relapsed or Refractory Multiple Myeloma (KEYNOTE-183): A Randomised, Open-Label, Phase 3 Trial
Lancet Haematol 2019 Jul 18;[EPub Ahead of Print], MV Mateos, H Blacklock, F Schjesvold, A Oriol, D Simpson, A George, H Goldschmidt, A Larocca, A Chanan-Khan, D Sherbenou, I Avivi, N Benyamini, S Iida, M Matsumoto, K Suzuki, V Ribrag, SZ Usmani, S Jagannath, EM Ocio, P Rodriguez-Otero, J San Miguel, U Kher, M Farooqui, J Liao, P Marinello, S LonialFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.